An ozempic user has called out a disgusting side effect and has issued a warning to others using the weight loss drug
While this is completely normal, a prolonged plateau could be a sign that the medication isnt working as it should
GLP-1 receptor agonists kicked off this trend, but now triple agonists such as retatrutide are being explored beyond obesity
United Healthcare, for example, typically covers it with prior authorization for BMI of 30 or higher, or a BMI of 27 with related health issues
However, these reports often lack detailed methodologies, making it difficult to assess the true impact of the peptide
Many patients wonder whether they can inject semaglutide above the belly button to reduce injection fatigue or improve comfort